NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...

Takeda Pharmaceutical Co. will get to arbitrate claims by a plaintiff that accused the company of delaying the generic ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Takeda is taking back the home license for a phase 3-ready depression drug as part of an amendment to its multi-asset ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...

Takeda Canada operates as the Canadian division of Takeda Pharmaceutical Company. Colorectal Cancer Canada CEO and president ...

Ballentine Partners LLC grew its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 24.3% in the 4th quarter, according to the company in its most recent filing ...

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.